Enpatoran in COVID-19 pneumonia: Safety and efficacy results from a phase II randomized trial.

Clin Transl Sci · 2023 · PMC10719456 · PMID 37873555

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

a numerical trendp = 0.054so close (0.05 < p ≤ 0.1)

Efficacy Primary outcome The primary efficacy end point of the time to recovery from Day 1 through Day 28 was not met, despite a numerical trend towards higher recovery rates in both enpatoran groups (50 mg b.i.d. n = 48, 88.9%, p = 0.054; 100 mg b.i.d. n = 42, 91.3%, p = 0.107) compared with the placebo group ( n = 37, 75.5%).

also in 227 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.